Jack F. Fowler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jack F. Fowler has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alan E. Nahum
University of Liverpool
1 shared publication - Colin G. Orton
Wayne State University
1 shared publication John D. Fenwick
Department of Human Oncology, Medical School of the University of Wisconsin, Madison, WI, USA
1 shared publication- Minesh P. Mehta
Miami Cancer Institute, Baptist Health South Florida, Miami, FL
1 shared publication - Wolfgang A Tom
Department of Human Oncology, University of Wisconsin Medical School, K4/344 CSC 600 Highland Avenue, Madison, WI 53792, USA
1 shared publication - Wolfgang A. Tomé
Montefiore Medical Center, Department of Radiation Oncology, Bronx, NY, USA; Albert Einstein College of Medicine, Institute for Onco-Physics, Bronx, NY, USA
1 shared publication
Latest Publications
- 1 March 2008
- Published by Elsevier in Clinical Oncology
- Vol. 20 (2) , 113-126
Optimum Overall Times II: Extended Modelling for Head and Neck Radiotherapy
- 1 March 2008
- Published by Elsevier in Clinical Oncology
- Vol. 20 (2) , 113-126
Optimum Overall Times II: Extended Modelling for Head and Neck Radiotherapy
- 1 February 2008
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 81 (962) , 89-90
Summary of meeting on “Radiobiological modelling in treatment planning” at the BIR on 12 December 2006
- 1 February 2008
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 81 (962) , 89-90
Summary of meeting on “Radiobiological modelling in treatment planning” at the BIR on 12 December 2006
- 1 February 2007
- Published by Elsevier in Clinical Oncology
- Vol. 19 (1) , 8-22
Is There an Optimum Overall Time for Head and Neck Radiotherapy? A Review, with New Modelling
- 1 February 2007
- Published by Elsevier in Clinical Oncology
- Vol. 19 (1) , 8-22
Is There an Optimum Overall Time for Head and Neck Radiotherapy? A Review, with New Modelling
- 11 August 2006
- Published by Wiley in Medical Physics
- Vol. 33 (9) , 3081-3084
The best radiotherapy for the treatment of prostate cancer involves hypofractionation
- 11 August 2006
- Published by Wiley in Medical Physics
- Vol. 33 (9) , 3081-3084
The best radiotherapy for the treatment of prostate cancer involves hypofractionation
- 20 June 2006
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 51 (13) , R263-R286
Development of radiobiology for oncology—a personal view
When I came into radiotherapy in 1950, I was puzzled that some patients were treated to 3000 rads (cGy) in 3 weeks but others received 4000 in 5 or 6000 in 6 weeks. When I asked why, there were no convincing answers given, except 'this is what we usually do'. It wasn't until I went to a course on 'Radiobiology for Radiotherapy' in Cambridge that I learnt about the basic theories of Douglas Lea and the very considerable history of research into radiobiology and clinical radiotherapy. And there were still some questions outstanding, such as the relative importance of intracellular repair between 'daily' fractions, whether a 2 day gap each week was a good or a bad idea, and the role of proliferation, if any, during irradiation. I thought that a few simple animal experiments might help to give answers! That led me to a continuing interest in these questions and answers, which has taken me more than 50 years to pursue. This is the very personal story of what I saw happening in the subject, decade by decade. I was happy to experience all this together with scientists in many other countries, and our own, along the way.
- 20 June 2006
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 51 (13) , R263-R286
Development of radiobiology for oncology—a personal view
When I came into radiotherapy in 1950, I was puzzled that some patients were treated to 3000 rads (cGy) in 3 weeks but others received 4000 in 5 or 6000 in 6 weeks. When I asked why, there were no convincing answers given, except 'this is what we usually do'. It wasn't until I went to a course on 'Radiobiology for Radiotherapy' in Cambridge that I learnt about the basic theories of Douglas Lea and the very considerable history of research into radiobiology and clinical radiotherapy. And there were still some questions outstanding, such as the relative importance of intracellular repair between 'daily' fractions, whether a 2 day gap each week was a good or a bad idea, and the role of proliferation, if any, during irradiation. I thought that a few simple animal experiments might help to give answers! That led me to a continuing interest in these questions and answers, which has taken me more than 50 years to pursue. This is the very personal story of what I saw happening in the subject, decade by decade. I was happy to experience all this together with scientists in many other countries, and our own, along the way.
- Open Access
- 1 May 2005
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 44 (3) , 265-276
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy
Total radiation dose is not a reliable measure of biological effect when dose-per-fraction or dose-rate is changed. Large differences in biological effectiveness (per gray) are seen between the 2 Gy doses of external beam radiotherapy and the large boost doses given at high dose-rate from afterloading sources. The effects are profoundly different in rapidly or slowly proliferating tissues, that is for most tumors versus late complications. These differences work the opposite way round for prostate tumors versus late complications compared with most other types of tumor. Using the Linear-Quadratic formula it is aimed to explain these differences, especially for treatments of prostate cancer. The unusually slow growth rate of prostate cancers is associated with their high sensitivity to increased fraction size, so a large number of small fractions, such as 35 or 40 “daily” doses of 2 Gy, is not an optimum treatment. Theoretical modeling shows a stronger enhancement of tumor effect than of late complications for larger (and fewer) fractions, in prostate tumors uniquely. Biologically Effective Doses and Normalized Total Doses (in 2 Gy fraction equivalents) are given for prostate tumor, late rectal reactions, and—a new development—acute rectal mucosa. Tables showing the change of fraction-size sensitivity (the alpha/beta ratio) with proliferation rates of tissues lead to the association of slow cell doubling times in prostate tumors with small α/β ratios. Clinical evidence to confirm this biological expectation is reviewed. The α/β ratios of prostate tumors appear to be as low as 1.5 Gy (95% confidence interval 1.3–1.8 Gy), in contrast with the value of about 10 Gy for most other types of tumor. The important point is that α/β=1.5 Gy appears to be significantly less than the α/β=3 Gy for late complications in rectal tissues. Such differences are also emerging from recent clinical results. From this important difference stems the superior schedules of, for example, 20 fractions of 3 Gy, or 10 fractions of 4.7 Gy, or 5 fractions of 7 Gy, which can all give tumor results equivalent to 80–90 Gy in 2 Gy fractions, while keeping late complications equivalent to only 72 Gy in 2 Gy fractions. Combination treatments of external beam (EBRT) and brachytherapy boost doses (25F×2 Gy plus 2×10 Gy) can give higher biological tumor effects than any EBRT using daily 2 Gy doses, and with acceptable late complications. Monotherapy by brachytherapy for low-risk cancer prostate using two to four fractions in a few days can give even higher biological effects on the tumors.
- 1 May 2005
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 44 (3) , 265-276
Open AccessThe radiobiology of prostate cancer including new aspects of fractionated radiotherapy
Total radiation dose is not a reliable measure of biological effect when dose-per-fraction or dose-rate is changed. Large differences in biological effectiveness (per gray) are seen between the 2 Gy doses of external beam radiotherapy and the large boost doses given at high dose-rate from afterloading sources. The effects are profoundly different in rapidly or slowly proliferating tissues, that is for most tumors versus late complications. These differences work the opposite way round for prostate tumors versus late complications compared with most other types of tumor. Using the Linear-Quadratic formula it is aimed to explain these differences, especially for treatments of prostate cancer. The unusually slow growth rate of prostate cancers is associated with their high sensitivity to increased fraction size, so a large number of small fractions, such as 35 or 40 “daily” doses of 2 Gy, is not an optimum treatment. Theoretical modeling shows a stronger enhancement of tumor effect than of late complications for larger (and fewer) fractions, in prostate tumors uniquely. Biologically Effective Doses and Normalized Total Doses (in 2 Gy fraction equivalents) are given for prostate tumor, late rectal reactions, and—a new development—acute rectal mucosa. Tables showing the change of fraction-size sensitivity (the alpha/beta ratio) with proliferation rates of tissues lead to the association of slow cell doubling times in prostate tumors with small α/β ratios. Clinical evidence to confirm this biological expectation is reviewed. The α/β ratios of prostate tumors appear to be as low as 1.5 Gy (95% confidence interval 1.3–1.8 Gy), in contrast with the value of about 10 Gy for most other types of tumor. The important point is that α/β=1.5 Gy appears to be significantly less than the α/β=3 Gy for late complications in rectal tissues. Such differences are also emerging from recent clinical results. From this important difference stems the superior schedules of, for example, 20 fractions of 3 Gy, or 10 fractions of 4.7 Gy, or 5 fractions of 7 Gy, which can all give tumor results equivalent to 80–90 Gy in 2 Gy fractions, while keeping late complications equivalent to only 72 Gy in 2 Gy fractions. Combination treatments of external beam (EBRT) and brachytherapy boost doses (25F×2 Gy plus 2×10 Gy) can give higher biological tumor effects than any EBRT using daily 2 Gy doses, and with acceptable late complications. Monotherapy by brachytherapy for low-risk cancer prostate using two to four fractions in a few days can give even higher biological effects on the tumors.
- 1 November 2004
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 60 (4) , 1241-1256
A challenge to traditional radiation oncology
- 1 November 2004
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 60 (4) , 1241-1256
A challenge to traditional radiation oncology
- 4 September 2003
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 48 (18) , N261-N268
On the inclusion of proliferation in tumour control probability calculations for inhomogeneously irradiated tumours
In previous modelling of tumour control probability (TCP) for inhomogeneously irradiated tumours we used an expression that did not include a proliferation correction term, which should be lambda(T - Tk). We did not use that term in the specific examples in our previous work to model slowly growing tumours in order to avoid unnecessary mathematical complexity. We have now considered how to do so in more detail, and there are some variations, such as schedules that depart from a number of equal fractions over the entire course of treatment, if one wishes to compensate for proliferation in the remaining fractions by increasing the dose per fraction after the kick-off time has passed in order to achieve the same TCP when proliferation is neglected.
- 4 September 2003
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 48 (18) , N261-N268
On the inclusion of proliferation in tumour control probability calculations for inhomogeneously irradiated tumours
In previous modelling of tumour control probability (TCP) for inhomogeneously irradiated tumours we used an expression that did not include a proliferation correction term, which should be lambda(T - Tk). We did not use that term in the specific examples in our previous work to model slowly growing tumours in order to avoid unnecessary mathematical complexity. We have now considered how to do so in more detail, and there are some variations, such as schedules that depart from a number of equal fractions over the entire course of treatment, if one wishes to compensate for proliferation in the remaining fractions by increasing the dose per fraction after the kick-off time has passed in order to achieve the same TCP when proliferation is neglected.